Celldex Therapeutics Inc - CLDX STOCK NEWS

Celldex Therapeutics (NASDAQ:CLDX) has presented positive preclinical data for CDX-622, their novel bispecific antibody targeting inflammatory and fibrotic disorders, at the AAAAI 2025 Annual Meeting. The antibody works by targeting both thymic stromal lymphopoietin (TSLP) and stem cell factor (SCF) pathways.

The preclinical studies demonstrated that CDX-622 effectively neutralizes both SCF and TSLP, reducing tissue mast cells and inhibiting Type 2 inflammatory responses. Key findings show the antibody inhibits inflammatory activities with similar potency to existing treatments, preferentially targets soluble SCF, and demonstrates favorable pharmacokinetic properties.

A Phase 1 study in healthy volunteers, initiated in November, is currently ongoing with initial data expected later in 2025. The compound showed strong safety profile in toxicology studies, with no adverse effects observed even at the highest dose level of 75 mg/kg.

Celldex Therapeutics (NASDAQ:CLDX) has announced positive results from Phase 2 studies of barzolvolimab in chronic urticaria patients. The drug, a humanized monoclonal antibody targeting KIT receptor, showed significant improvements in both chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) patients.

Key findings from the 52-week CSU study include:

• Up to 71% of patients achieved complete response
• 82% reported symptoms no longer impacted quality of life
• 95% reported meaningful quality of life improvement

In the 12-week CIndU study:

• 53% of ColdU and 58% of SD patients achieved complete response
• 60% reported symptoms no longer impacted quality of life
• 69% reported well-controlled urticaria

Global Phase 3 studies (EMBARQ-CSU1 and EMBARQ-CSU2) are currently enrolling, with plans to advance to Phase 3 for CIndU in 2025.

Celldex Therapeutics (NASDAQ:CLDX) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical programs. The company's lead drug barzolvolimab showed promising results in chronic urticarias, with Phase 3 studies actively enrolling patients globally.

Financial highlights include:

• Cash position of $725.3 million as of December 31, 2024
• Q4 2024 revenue of $1.2 million
• Full-year 2024 revenue of $7.0 million
• Q4 net loss of $47.1 million ($0.71 per share)
• Full-year net loss of $157.9 million ($2.45 per share)

The company initiated new programs including a Phase 2 study in atopic dermatitis and launched CDX-622, their first inflammatory bispecific candidate. Multiple data readouts are expected in 2025, with current cash runway extending through 2027.

Celldex Therapeutics (NASDAQ:CLDX) has initiated a Phase 2 study of barzolvolimab in atopic dermatitis (AD), a common chronic inflammatory skin disease affecting up to 20% of the US population. The study will evaluate approximately 120 patients with moderate to severe AD, randomized to receive either 150mg or 300mg of barzolvolimab or placebo every 4 weeks.

The 32-week trial includes a 16-week placebo-controlled phase followed by a 16-week active treatment phase. The primary endpoint will measure itch intensity reduction using the Peak Pruritus Numerical Rating Scale at Week 16. The study will be conducted across up to 50 clinical trial centers in the United States.

Celldex Therapeutics (NASDAQ:CLDX) has initiated dosing in its Phase 1a study of CDX-622, a bispecific antibody targeting inflammatory diseases. The study will evaluate safety, pharmacokinetics, and pharmacodynamics in up to 56 healthy volunteers. CDX-622 targets two inflammatory pathways by neutralizing TSLP and depleting mast cells via SCF starvation. The trial consists of two parts: single ascending doses and multiple ascending doses administered intravenously every 3 weeks. A subcutaneous formulation will be added to the study in 2025. The company aims to expand into asthma studies following successful completion of this trial.

Celldex Therapeutics (NASDAQ:CLDX) has announced its management's upcoming participation in two major healthcare investor conferences. The company will engage in fireside chats at the Guggenheim Healthcare Innovation Conference on November 12th at 4:00 p.m. ET and the 7th Annual Evercore HealthCONx Conference on December 3rd at 4:15 p.m. ET. Both presentations will be available via live webcasts on the company's website under the 'Events & Presentations' section, with replays accessible for 90 days after each event.

Celldex Therapeutics (NASDAQ:CLDX) announced positive Phase 2 clinical trial results for barzolvolimab in treating chronic inducible urticaria (CIndU). The study met all primary and secondary endpoints with high statistical significance in patients with cold urticaria and symptomatic dermographism who were unresponsive to antihistamines. The trial demonstrated significant improvements in both 150mg and 300mg dosing groups compared to placebo, with up to 53.1% of cold urticaria patients and 57.6% of symptomatic dermographism patients achieving complete response. The drug showed a favorable safety profile, with mostly Grade 1 adverse events. The company plans to advance to Phase 3 development in 2025.

Celldex Therapeutics (NASDAQ:CLDX) announced upcoming presentation of 12-week results from their Phase 2 clinical trial of barzolvolimab in chronic inducible urticaria (CIndU). The study focused on two common forms: cold urticaria and symptomatic dermographism. The presentation, titled 'Positive Efficacy and Favorable Safety of Barzolvolimab in Chronic Inducible Urticaria: Phase 2 Trial Results,' will be delivered as a late-breaking oral presentation at the American College of Allergy, Asthma & Immunology's Annual Scientific Meeting in Boston on October 26th, 2024.

Celldex Therapeutics (NASDAQ:CLDX) presented 52-week results from their Phase 2 study of barzolvolimab in chronic spontaneous urticaria (CSU) at EADV 2024. Key findings include:

- 71% of patients on 150 mg Q4W achieved complete response at Week 52
- Rapid and durable improvement in UAS7 starting Week 1
- Robust improvement across omalizumab-experienced/refractory/naïve patients
- Well-tolerated safety profile through 52 weeks

The study met its primary endpoint with significant UAS7 improvement across all dose groups. Barzolvolimab targets mast cells by binding to KIT receptor, inhibiting mast cell function and survival. Global Phase 3 CSU trials are now enrolling patients.